Abstract
Biologics available in severe asthma target IgE (omalizumab), IL-5 (mépolizumab, reslizumab), IL-5 receptor (benralizumab) and IL-4/IL-13 receptor (dupilumab). The pharmacokinetic profile of these drugs is related to their IgG structure and characterized by slow elimination. Biotherapies are indicated in severe asthma caused by allergic and/or eosinophilic inflammation. The main therapeutic effect is a reduction in the frequency of severe exacerbations, responsible for emergency room visits and hospitalizations. Several molecules significantly reduce the continuous oral glucocorticoid dose, while asthma control is maintained. Given the current state of knowledge, biologics have a favorable safety profile, with common side effects including injection site reaction and a low risk of anaphylaxis. New biologics are tested in clinical trials, which may provide exciting new directions in the treatment of severe asthma, especially in non-allergic and non-eosinophilic asthma.© 2020 SPLF. Published by Elsevier Masson SAS. All rights reserved.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
